Interventional device developer Boston Scientific of Natick, MA, has received approval from Health Canada’s Therapeutic Products Directorate for the sale of its Taxus Express2 paclitaxel-eluting coronary stent system in Canada.
The Taxus stent system is designed to treat coronary restenosis, the growth of neointimal tissue within an artery after angioplasty and stenting. It has previously been approved for sale in Europe and other international markets and is awaiting approval by the Food and Drug Administration, according to the firm.
Boston Scientific said it plans to launch the product immediately in Canada.
By AuntMinnie.com staff writersSeptember 12, 2003
Related Reading
Boston Scientific, CryoVascular form alliance, September 11, 2003
Boston Scientific adds to IVUS offerings, August 14, 2003
Boston Scientific seeks stock split, July 30, 2003
Boston Scientific shows Q2 uptick, July 23, 2003
Boston Scientific submits final module for Taxus trials, June 19, 2003
Copyright © 2003 AuntMinnie.com
